Overview

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Status:
Terminated

Trial end date:
2020-01-16

Target enrollment:

Participant gender:

Summary

The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Dexamethasone